Company news

Krystal Biotech, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

November 5, 2024

Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates

November 3, 2024

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

October 27, 2024

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

September 12, 2024

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 5, 2024

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

August 27, 2024

Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates

August 4, 2024

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

July 25, 2024

Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 14, 2024

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 7, 2024

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 5, 2024

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

May 1, 2024

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

April 25, 2024

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

April 21, 2024

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

April 3, 2024

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

February 27, 2024

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

February 25, 2024

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

February 19, 2024

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

February 12, 2024

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

February 7, 2024

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

January 31, 2024

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

January 3, 2024

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

December 18, 2023

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

November 26, 2023

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

November 8, 2023

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

November 5, 2023

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

October 29, 2023

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

September 27, 2023

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

September 20, 2023

Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 6, 2023

Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

September 4, 2023

Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

August 20, 2023

Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights

August 6, 2023

Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

July 25, 2023

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis

July 2, 2023

Krystal Biotech to Present at Upcoming Investor Conferences

June 4, 2023

Krystal Biotech Announces $160 Million Private Placement Equity Financing

May 21, 2023

Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

May 18, 2023

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

May 7, 2023

Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program

April 23, 2023

Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest

April 17, 2023

Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting

April 12, 2023

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

March 5, 2023

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

March 1, 2023

Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

February 26, 2023

Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

January 17, 2023

Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

January 8, 2023

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

December 13, 2022

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

December 4, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.